C4 Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Filed September 25, 2026, under Items 7.01 and 8.01. The filing reports new biomarker data and clinical development updates for cemsidomide in relapsed/refractory multiple myeloma (RRMM), presented at the 23rd International Myeloma Society Annual Meeting.
Key Clinical and Other Metrics
- Phase 1 cemsidomide plus dexamethasone: Data from 62 heavily pre-treated RRMM patients across once-daily dose levels showed coordinated T-cell activation, including CD8+ T cells, and functional reprogramming of natural killer cells.
- Enhanced immune-cell function was observed at the 75 µg and 100 µg dose levels, which the company stated also achieved compelling overall response rates; specific response-rate percentages were not provided in the filing text.
- Phase 1b cemsidomide plus elranatamab: Preliminary biomarker data from the first two patients who completed Cycle 1 showed expansion and activation of CD8+ effector memory T cells, measured by elevated HLA-DR, and reduced markers associated with T-cell exhaustion, including PD-1, TIM-3, and LAG3.
- Following review of the first six-patient safety cohort, the safety data review committee declared the 75 µg dose safe in combination with elranatamab.
Material Changes and Outlook
- The Phase 1b study is advancing to a dose-escalation safety cohort at 100 µg and an expansion cohort at 75 µg.
- Data from all Phase 1b cohorts are expected in mid-2027.
- The filing characterizes the initial biomarker findings as positive translational and mechanistic support for cemsidomide as a potential combination partner for immune-based therapies.
Financial Position, Liquidity, and Unusual Items
This Form 8-K does not report revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity metrics, or changes in financial condition. No financial guidance was provided. The filing states that access to sufficient capital to fund future operations is a risk.
Risks and Contingencies
- Biomarker findings and signs of biological activity may not predict long-term clinical outcomes or translate across programs or patient populations.
- Clinical-study initiation, timing, advancement, conduct, and development requirements remain uncertain.
- Cemsidomide or other product candidates may cost more to develop than anticipated or may not be successfully developed or commercialized.
- The company may not obtain sufficient capital on acceptable terms or when required.
- Statements regarding clinical significance, immune-cell effects, study advancement, and the timing of future data are forward-looking and subject to material risks.
Important Facts for Investors to Verify
- Review Exhibits 99.1 and 99.2 for the complete biomarker data, response rates, safety results, patient characteristics, and supporting presentation materials.
- Confirm the basis and scope of the statement that the 75 µg dose was safe, including the number of patients and duration of follow-up.
- Assess whether the two-patient Phase 1b biomarker dataset is sufficiently mature to support conclusions regarding efficacy or durability.
- Monitor execution of the 100 µg dose-escalation and 75 µg expansion cohorts and whether mid-2027 data timing is achieved.
- Review the company’s latest Form 10-K and Form 10-Q for cash runway, financing needs, operating results, and related risk factors.